The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.01.011
Abstract: Indoleamine 2,3-dioxygenase (IDO, also referred to as IDO1) has been demonstrated to be a normal endogenous mechanism of acquired peripheral immune tolerance in vivo. In the field of oncology, IDO expression and/or activity has been observed… read more here.
Keywords: rationale indoleamine; inhibition; dioxygenase inhibition; cancer ... See more keywords